Semaglutide ni imiti igabanya glucose yakozwe na Novo Nordisk yo kuvura diyabete yo mu bwoko bwa 2. Muri Kamena 2021, FDA yemeye Semaglutide yo kwamamaza nk'umuti ugabanya ibiro (izina ry'ubucuruzi Wegovy). Uyu muti ni glucagon imeze nka peptide 1 (GLP-1) reseptor agonist ishobora kwigana ingaruka zayo, kugabanya inzara, bityo bikagabanya indyo na calorie, bityo bigira akamaro mukugabanya ibiro.
Usibye gukoreshwa mu kuvura diyabete yo mu bwoko bwa 2 n'umubyibuho ukabije, Semaglutide yasanze kandi irinda ubuzima bw'umutima n'imitsi, kugabanya ibyago bya kanseri, no gufasha kureka kunywa. Byongeye kandi, ubushakashatsi bubiri buherutse gukorwa bwerekanye ko Semaglutide ishobora kandi kugabanya ibyago byo kurwara impyiko zidakira n'indwara ya Alzheimer.
Ubushakashatsi bwibanze bwerekanye ko kugabanya ibiro bishobora kugabanya ibimenyetso bya osteoarthritis yo mu ivi (harimo no kugabanya ububabare). Nyamara, ingaruka z'imiti igabanya ibiro bya GLP-1 agonist nka Semaglutide ku ngaruka za osteoarthritis yo mu ivi ku bantu bafite umubyibuho ukabije ntabwo yakozwe neza.
Ku ya 30 Ukwakira 2024, abashakashatsi bo muri kaminuza ya Copenhagen na Novo Nordisk basohoye inyandiko y’ubushakashatsi yiswe: Semaglutide rimwe mu cyumweru mu bantu bafite umubyibuho ukabije na Knee Osteoarthritis mu kinyamakuru cy’ubuvuzi mpuzamahanga cy’Ubwongereza (NEJM), ikinyamakuru mpuzamahanga cy’ubuvuzi mpuzamahanga.
Ubu bushakashatsi bw’amavuriro bwerekanye ko semaglutide ishobora kugabanya cyane ibiro kandi igabanya cyane ububabare buterwa n’umubyibuho ukabije w’amavi (ingaruka zidakira zihwanye n’iza opioide), kandi zikongerera ubushobozi bwo kwitabira siporo. Ni ku nshuro ya mbere kandi ubwoko bushya bw'imiti igabanya ibiro, GLP-1 reseptor agonist, byemejwe kuvura indwara ya rubagimpande.
Igihe cyoherejwe: Gashyantare-27-2025